We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Ionis Pharmaceuticals Inc | NASDAQ:IONS | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.08 | 0.19% | 43.09 | 40.34 | 44.85 | 43.62 | 42.62 | 43.15 | 666,268 | 01:00:00 |
By Colin Kellaher
Biogen Inc. (BIIB) Wednesday said it will launch a new study to evaluate whether a higher dose of Spinraza can provide greater efficacy in the treatment of the neuromuscular disease spinal muscular atrophy.
The Cambridge, Mass., biopharmaceutical company said it will conduct the phase 2/3 study at 50 sites around the world, with a projected enrollment of 126 patients of all ages.
Biogen said the trial will compare two loading doses of 50 milligrams 15 days apart followed by a maintenance dose of 28 milligrams every four months with the current FDA-approved program of four loading doses with 12-milligram maintenance doses every four months.
Spinal muscular atrophy is a rare genetic disease characterized by a loss of motor neurons in the spinal cord and lower brain stem, resulting in severe, progressive muscle atrophy and weakness.
Biogen licensed the global rights to develop, manufacture and commercialize Spinraza from Ionis Pharmaceuticals Inc. (IONS), which receives royalties on sales of the drug.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
September 18, 2019 08:07 ET (12:07 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
1 Year Ionis Pharmaceuticals Chart |
1 Month Ionis Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions